Keyword: Nanjing Legend Biotech
2. Paul Stoffels, Johnson & Johnson
In the 57 patients who received the treatment, the overall response rate was 88%, with 74% having a complete response.
GenScript shares plummeted yesterday on allegations of data falsification in a CAR-T program, only to rebound after it strongly denied the claims.
Johnson & Johnson is paying $350 million upfront to join forces with Legend as they look for a working “cure” for certain blood cancers.
Nanjing Legend Biotech's CAR-T candidate could be a safe and effective way to treat relapsed or refractory multiple myeloma